Blinger Ingehan is involved in the European New Crown Acceleration Research and Development Project, focusing on the development of new crown virus-specific antibodies.

Guide: With the support of the European Alliance for Innovative Drugs (IMI), CARE (European New Crown Accelerated Research and Development) is scheduled to be launched today to accelerate the discovery and development of urgently needed drugs to fight the new coronavirus that causes new coronary pneumonia.
supported by the European Innovative Medicines Initiative (IMI), CARE (European New Crown Accelerated Research and Development) is the largest collaborative project of its kind to identify and develop treatments for the urgent need for new crown pneumonia.
The program is committed to understanding long-term trends in new coronary pneumonia, accelerating the development of treatments for new coronary pneumonia and future coronavirus threats, and promoting the re-use of existing therapies with a view to their immediate use in the fight against new coronary pneumonia."
CARE Alliance brings together 37 teams from academia, non-profit research institutions and pharmaceutical companies to accelerate the development of new coronary pneumonia therapies by integrating their leading expertise and projects into a comprehensive drug discovery engine.
will lead a working group in the alliance focused on virus and antibody development.
BRUSSELS, Belgium, August 18, 2020 /US NEWS/ -- CARE (European New Crown Accelerated Research and Development) is scheduled to be launched today with the support of the European Alliance for Innovative Drugs (IMI), with the aim of accelerating the discovery and development of urgently needed drugs to fight the new coronavirus that causes new coronary pneumonia.
total allocation for the
CARE project will amount to Euro77.7 million, with cash contributions from the European Union and cash and in-kind contributions from 11 member companies of the European Federation of Pharmaceutical Industry Associations (EFPIA) and three IMI-affiliated partners. the
CARE program will last for five years, bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the United Kingdom and the United States, led by VRI-Inserm in Paris, France, Janssen Pharmaceuticals in Beerse, Belgium, and Takeda Pharmaceuticals International in Zurich, Switzerland.
the project will integrate the new crown research project that partners have been working on since February 2020.
a member of the CARE Alliance, Blinger Ingehan will lead a working group in the Alliance focused on virus and antibody development.
addition, the company will screen out antiviral molecular drugs from its existing anti-HIV and hepatitis C virus (HCV) products, as well as a complete screening of its own molecular library to select small molecule candidates.
Clive R. Wood, Senior Vice President and Head of Global Discovery Research at Blinger Ingeham, said, "The CARE Alliance aims to unleash the power of open science and cooperation to serve society as a whole.
we will work with our academic and industry partners to act quickly and decisively in a spirit of unprecedented cooperation to fight off the unprecedented threat posed by new coronary pneumonia and other serious coronavirus diseases. "We are excited to launch the CARE Alliance to work with other top experts to accelerate the development of much-needed new drugs to respond to new coronaviruses and other coronaviruses that could lead to outbreaks," added Marnix Van Loock, senior scientific director of global public health at janssen Pharmaceuticals and head of emerging pathogen research and development at
.
As part of this program, we will make full use of our on-the-job new crown drug research project with the Rega Institute of Medicine at the University of Leuven to screen out a drug reusable bank from thousands of existing drug compounds.
, Director of External Cooperation for Global Research at Takeda, said: "It is shocking to see so many of Europe's top scientific talents come together to address this complex issue with such urgency.
for our generation, the new coronary pneumonia is a once-in-a-lifetime scientific challenge.
care is designed to create effective treatments with positive safety for current and future coronavirus outbreaks.
we want to act quickly and make a meaningful impact in a timely manner.
's comprehensive short- and long-term response care program for new coronary pneumonia aims to create an effective treatment (drug reuse) with positive safety for the new coronary pneumonia pandemic, while developing new drugs and antibodies specifically designed to respond to the new coronary virus.
alliance is based on three pillars: drug reuse: screening and analyzing a library of compounds provided by partners to rapidly move drug molecules into late-stage clinical trials.
small molecule drug discovery: through computer screening and analysis, to find out the direct effect of the new coronavirus and future coronavirus target candidate drugs.
virus and antibody discovery: make full use of all human-sourced phages and yeast displays, immuno-related humanized animal models, patient B cells, and computer design.
alliance has built different working groups around these three pillars to refine candidate compounds, focusing on comprehensive drug chemistry research, systems biology research, and preclinical and clinical evaluation of drug molecules from the three pillars.
systems biology will look at the pathophysiology of viruses to help us better understand the interaction between viral infection stages and human immune responses.
researchers will look for disease markers, provide information for the development of therapies, improve clinical trial design, and monitor the development of phases 1 and 2 clinical trials of new drugs under the CARE program.
, there is no new coronary virus vaccine approved worldwide, and the treatment of new coronary pneumonia is very limited.
, however, the outbreak is still spreading, with many confirmed and fatal cases every day.
Based on a unique spirit of collaboration, the CARE project brings together the most innovative and experienced scientists in all relevant fields and maximizes synergy and complementarity with other research and development projects (e.g., the New Coronary Pneumonia Treatment Accelerator, the New Crown Virus Monoclonal Antibody Program (MANCO), the Coronavirus Treatment Rapid Response Program (SCORE), the European Alliance for Clinical Research on Infectious Diseases (ECRAID), and accelerates the development of solutions for current coronary pneumonia outbreaks.
laboratory tests, the project will push the most promising candidate drugs into human clinical trials.
Yves Levy, executive director of VRI-Inserm and coordinator of the CARE project, said: "The new crown pneumonia pandemic has become the greatest global health threat facing humanity this century, requiring the global scientific community to come together in a way unprecedented.
CARE is an ambitious project that will go beyond each team's superior research capabilities and bring together 37 partners to bring together their expertise and know-how to work together over the next five years to develop therapies for the current new crown outbreak.
are very grateful to the European Innovative Medicines Initiative for its financial support, which has enabled us to implement this program.
About CARECARE is a new public-private partnership that brings together scientists from academia, research centres, small and medium-sized enterprises, member companies of the European Federation of Pharmaceutical Industry Associations (EFPIA) and IMI affiliated partners, including a total of 37 different partner organizations.
Professor Yves Levy from VRI-Inserm served as academic coordinator, Marnix Van Loock from Johnson and Johnson's Jansen Pharmaceuticals served as EFPIA project leader and Kumar Saikatendu from Takeda served as co-head of the project. Partners in the
program include 11 academic institutions (KUL, GUF, AMU, UzLUU, EDI-IVI, UHAM, UEDIN, TiHo, JU, LUMC), 5 public research organizations (Inserm, CHUV, CEA, HZI, SERMAS), 7 small and medium-sized enterprises (IT, EVF, EXSCI, NUVISAN, SCIFEON, ENYO and AIB), 11 EFPIA members (Janssen, Takeda, Pfizer, ABBV, BI, MerckKgA, BAG, Novartis, Astellas, Servier and AiCuris) and 3 IMI2 affiliated partners (BMGF, UNIVDUN, GHDDI).
!-- 5f39ae17-8c62-4a45-bc43-b32064c9388a: W3siYmxvY2tJ ZCI6IJIxNTATTU5NzgwMzk1NDQwNCIsImJsb2NrVHlwZSI6 Imlt YWdl Iiwic3R5bGVzIjp7ImJh Y2stY29sb3IiOiIILCJwYWRkaW5n Ijoi Iiwia GVpZ2h0Ijox MSwid2lkd Ggi OjYMH0sInR5c GUioioi JpbWFnZSIsInNvdXJjZSI6IjFCNEU0NEE5MTRCMDQWRDRCNTI4RjdBNTRGMZBFNDRFFFIn1d.